SAVA Global is proud to announce the release of their next generation dry powder inhalers.
PUNE, MAHARASHTRA, INDIA, July 2, 2018 /EINPresswire.com/ — SAVA Global’s Research and Development Center has been working tirelessly to make the treatment of asthma and asthma-like symptoms easier, more effective, and more efficient.
SAVA Global understands the importance of dry powder inhalers and has worked hard to make even more improvements on an already great product. SAVA’s Research and Development Center in Pune, India, aided by best-in-class research and development equipment like the Dosage Unit Sampling Apparatus (DUSA), NextGen Impactor (NGI), and Glass Twin Impinger (T1, T2), are ready to announce their new DPI’s: Tiotropium, Formoterol, salmeterol/fluticasone, and Budesonide/Formoterol Fumarate.
Within the global healthcare market, research and development of dry powder inhalers (DPI’s) continue to grow immensely. Many attribute this to their effectiveness, some to their ease of use, but the biggest catalyst for this demand for more and better DPI’s is the increasing incidence of chronic obstructive pulmonary disease (COPD). DPI’s provide a much more efficient delivery system for asthma treatment, an efficiency that is fast becoming a necessity as more people are showing symptoms of COPD across the globe. By easing the delivery of medication through pulmonary routes, COPD sufferers using DPI’s can avoid the potential complications caused by traditional delivery systems.
Under the leadership of Vinod Ramchandra Jadhav, SAVA Global has developed these new dry powder inhalers based on scientific research and data to make them better for everyone who needs them. SAVA’s new DPI’s are easy to use, compact, and efficient. Dry powder inhalers are a great alternative to traditional aerosol-based inhalers (MDI’s) because they deliver medication without requiring the user to coordinate his or her breath with the inhaler. Because they use dry powder, DPI’s can deliver treatment to the lungs more quickly. People suffering from asthma, bronchitis, emphysema, and COPD can receive their treatment quicker, easier, and much more effectively.
With the announcement of these new DPI’s, SAVA Global continues to establish itself as a trailblazer in the healthcare market. SAVA Global is looking toward the future and creating a path to innovation that everyone can follow.
For more information visit: http://www.savaglobal.com/
About Vinod Ramchandra Jadhav: Mr. Jadhav is a first generation entrepreneur with a passion for business. In 2001, he began operating as a franchises owner of a “Medicine Shoppe International” where he learned the ropes of the pharmaceutical industry and got the experience he needed to apply his knowledge of supply chain management on a larger scale. In 2003, he started SAVA Group and has grown the company into an international powerhouse that has footprints in 35 countries around the world. Since then Jadhav has taken his talents to several companies. In addition to being Chairman of SAVA Global, he is Chairman of DEVTECH M2M Group, Director of GangaGen Inc. and Managing Director of Regent Global FZCo.
Vinod Ramchandra Jadhav
SAVA Healthcare Limited
email us here
Source: EIN Presswire